The Scripps Research Institute and Sandoz Pharmaceuticals Extend Contract Deadline

La Jolla, CA. July 1, 1993 -- In an attempt to ensure that their proposed research collaboration serves the best interests of science and the American public while addressing issues raised by the National Institutes of Health, The Scripps Research Institute and Sandoz Pharmaceuticals have agreed to extend the July 1 deadline for consummating the funding arrangement.

The two organizations remain firmly committed to working together toward a timely resolution that fully addresses NIH’s concerns over issues of public policy that relate to public-private scientific collaborations. Scripps officials acknowledged their willingness to compromise while emphasizing their belief that the original arrangement rigorously adheres to the provisions of the Bayh-Dole Act.

According to William H. Beers, Ph.D., Senior Vice President, "Institutions such as Scripps must seek alternative sources of funding other than the Federal government to maintain the pace of research and this country’s preeminence in the biosciences. It is in this context," he continued, "that we have entered into this most recent technology transfer arrangement as we have done with other corporate partners for the last decade. Without such technology transfer agreements, important therapies would never find their way from the laboratory to the public where they provide the most benefit."

###